Where has reactive amyloidosis gone?;Qu'est devenue l'amylose de l'inflammation?

Revue du Praticien

Volumn 53, Issue 5, 2003, Pages 516-519

  Grateau, Gilles ^a  

^a HÔpital Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; CONGO RED; IMMUNOSUPPRESSIVE AGENT;

AMYLOIDOSIS; CHRONIC INFLAMMATION; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; GENETICS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY DISEASE; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; POLYARTHRITIS; PREVALENCE; PROTEINURIA; REVIEW; RHEUMATOID ARTHRITIS; SCREENING; STAINING; TREATMENT INDICATION;

AMYLOIDOSIS; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; HUMANS; INCIDENCE; INFLAMMATION; PROGNOSIS; RISK FACTORS;

EID: 0037345928     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Hazenberg BP, van Rijswijk MH. Amylose AA. In: Grateau G, Benson MD, Delpech M (eds). Les amyloses. Paris: Flammarion Médecine-Sciences; 2000: 377-405.
2. Hazenberg BP, van Rijswijk MH. Where has secondary amyloid gone? Ann Rheum Dis 2000; 59: 577-9.
3. Simms RW, Prout MN, Cohen AS. The epidemiology of AL and AA amyloidosis. In: Husby G (ed). Reactive amyloidosis and the acute phase response. Baillière's Clinical Rheumatology. London: Baillière's Tindall; 1994: 627-34.
4. Brandt K, Cathcart ES, Cohen AS. A clinical analysis of the course and prognosis of forty-two patients with amyloidosis. Am J Med 1968; 44: 955-69.
5. Janssen S, Van Rijswijk MH, Meijer S et al. Clinical evaluation of AA and AL amyloid disease. In: Marrink J, Van Rijswijk MH (eds). Amyloidosis, Dordrecht: Martinus Nijhoff Publishers; 1986: 61-72.
6. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 1991; 70: 246-56.
7. Lachmann HJ, Gilbertson JA, Gillmore JD, Hawkins PN, Pepys MB. Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. QJM 2002; 95: 211-8.
8. Gomez-Casanovas E, Sanmarti R, Sole M, Canete JD, Munoz-Gomez J. The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum 2001; 44: 66-72.
9. Ylinen K, Gronhagen-Riska C, Honkanen E, Ekstrand A, Metsarinne K, Kuhlback B. Outcome of patients with secondary amyloidosis in dialysis treatment. Nephrol Dial Transplant 1992; 7: 908-12.
10. Villamil CF, Massimi G, D'Avella J, Cole SR. Amyloid goiter with parathyroid involvement: a case report and review of the literature. Arch Pathol Lab Med 2000; 124: 281-3.
11. Baba S, Masago SA, Takahashi T et al. A novel allelic variant of serum amyloid A, SAAI gamma: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet 1995; 4: 1083-7.
12. Berglund K, Thysell H, Keller C. Results, principles and pitfalls in the management of renal AA-amyloidosis; a 10-21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol 1993; 20: 2051-7.
13. Chevrel G, Jenvrin C, McGregor B, Miossec P. Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide. Rheumatol 2001; 40: 821-5.
14. Deschenes G, Prieur AM, Hayem F, Broyer M, Gubler MC. Renal amyloidosis in juvenile chronic arthritis: evolution after chlorambucil treatment. Pediatr Nephrol 1990; 4: 463-9.
15. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1995; 1: 143-8.
16. Pepys MB, Herbert J, Hutchinson WL et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002; 417: 254-9.